Comparison Reveals Human Physicians Outperform Virtual Diagnosticians
|
By LabMedica International staff writers Posted on 26 Oct 2016 |

Image: A study comparing diagnostic accuracy of physicians versus symptom checker apps and Internet programs suggests that reliable computer diagnostics is as yet a distant goal (Photo courtesy of Harvard University Medical School).
Increasingly powerful computers using ever-more sophisticated programs are challenging human supremacy in diverse areas. Can current digital diagnostics programs outperform, or even match, human physicians? The answer, according to a new study, is still “far from it.”
The findings of the study, led by researchers at Harvard University Medical School (Boston, MA, USA), show that physicians’ performance is vastly superior as they made a correct diagnosis more than 2x as often as 23 commonly used symptom-checkers. The analysis is believed to be the first direct comparison between human-made and computer-based diagnoses.
Diagnostic errors stem from failure to recognize a disease or to do so in a timely manner. Physicians make such errors roughly 10-15% of the time, researchers say. Over the last two decades, computer-based checklists and other digital apps have been increasingly used to reduce medication errors or streamline infection-prevention protocols. Lately, experts have wondered whether computers might also help improve clinical diagnoses and reduce diagnostic errors. Many people use apps or Internet programs to check their symptoms or to self-diagnose, yet how these computerized symptom-checkers fare against physicians has not been well studied.
In the study, 234 internal medicine physicians were asked to evaluate 45 clinical cases, involving both common and uncommon conditions with varying degrees of severity. For each scenario, physicians had to identify the most likely diagnosis along with two additional possible diagnoses. Each clinical vignette was solved by at least 20 physicians.
The physicians outperformed the symptom-checker apps, listing the correct diagnosis first 72% of the time, compared with 34% of the time for the digital platforms. 84% of clinicians listed the correct diagnosis in the top 3 possibilities, compared with 51% for the digital symptom-checkers. The difference between physician and computer performance was most dramatic in more severe and less common conditions, and smaller for less acute and more common illnesses.
“While the computer programs were clearly inferior to physicians in terms of diagnostic accuracy, it will be critical to study future generations of computer programs that may be more accurate,” said senior investigator Ateev Mehrotra, associate professor of healthcare policy HMS.
Despite outperforming the machines, physicians still made errors in about 15% of cases. Developing computer-based algorithms to be used in conjunction with human decision-making may help further reduce diagnostic errors. “Clinical diagnosis is currently as much art as it is science, but there is great promise for technology to help augment clinical diagnoses,” said Prof. Mehrotra, “That is the true value proposition of these tools.”
The study, by Semigran HL et al, was published online October 10, 2016, in the journal JAMA Internal Medicine.
Related Links:
Harvard University Medical School
The findings of the study, led by researchers at Harvard University Medical School (Boston, MA, USA), show that physicians’ performance is vastly superior as they made a correct diagnosis more than 2x as often as 23 commonly used symptom-checkers. The analysis is believed to be the first direct comparison between human-made and computer-based diagnoses.
Diagnostic errors stem from failure to recognize a disease or to do so in a timely manner. Physicians make such errors roughly 10-15% of the time, researchers say. Over the last two decades, computer-based checklists and other digital apps have been increasingly used to reduce medication errors or streamline infection-prevention protocols. Lately, experts have wondered whether computers might also help improve clinical diagnoses and reduce diagnostic errors. Many people use apps or Internet programs to check their symptoms or to self-diagnose, yet how these computerized symptom-checkers fare against physicians has not been well studied.
In the study, 234 internal medicine physicians were asked to evaluate 45 clinical cases, involving both common and uncommon conditions with varying degrees of severity. For each scenario, physicians had to identify the most likely diagnosis along with two additional possible diagnoses. Each clinical vignette was solved by at least 20 physicians.
The physicians outperformed the symptom-checker apps, listing the correct diagnosis first 72% of the time, compared with 34% of the time for the digital platforms. 84% of clinicians listed the correct diagnosis in the top 3 possibilities, compared with 51% for the digital symptom-checkers. The difference between physician and computer performance was most dramatic in more severe and less common conditions, and smaller for less acute and more common illnesses.
“While the computer programs were clearly inferior to physicians in terms of diagnostic accuracy, it will be critical to study future generations of computer programs that may be more accurate,” said senior investigator Ateev Mehrotra, associate professor of healthcare policy HMS.
Despite outperforming the machines, physicians still made errors in about 15% of cases. Developing computer-based algorithms to be used in conjunction with human decision-making may help further reduce diagnostic errors. “Clinical diagnosis is currently as much art as it is science, but there is great promise for technology to help augment clinical diagnoses,” said Prof. Mehrotra, “That is the true value proposition of these tools.”
The study, by Semigran HL et al, was published online October 10, 2016, in the journal JAMA Internal Medicine.
Related Links:
Harvard University Medical School
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more






 Analyzer.jpg)
